The PI3K pathway as drug target in human cancer.

By K. Courtney, R. Corcoran, J. Engelman. Journal of Clinical Oncology, 2010

1,284 citations recorded by the source corpus.

Subfields: Molecular Biology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/eb0c51fa6059b1d5b8794a3ca29b45bcf77f51bd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Pathology and Forensic Medicine

Citations in the corpus

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. (2014, background): “As a result of the high selectivity of idelalisib for PI3Kd, patients did not show the elevations of serum glucose, insulin, or proinsulin C-peptide levels that are characteristically observed in patients receiving pan–PI3Kinhibitors that also inhibit PI3Ka.(16,17) Asmeasured in vivo using patient C”
Cancer genomics: from discovery science to personalized medicine (2011, background): “Indeed, the combination of PI(3)K pathway inhibitors with inhibitors of receptor protein tyrosine kinases (for example, insulin-like growth factor receptor (IGFR) or EGFR), mTOR or MEK are currently under clinical development and hold promise, if a suitable therapeutic window can be achieved for the”
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches (2012, background): “Exon 9 mutations (E545K and E542K) alter the helical domain of p110a, while exon 20 mutations (H1047R) lead to changes in the kinase domain [1].”
Treatment of HER2-positive breast cancer: current status and future perspectives (2012, background): “Inhibition of the PI3K pathway The PI3K family is complex, consisting of multiple members, divided into three main classes”
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. (2012, background): “Preclinical studies of inhibitors of PI3K signaling have shown antiproliferative activity in cancer cells and inhibition of tumor growth in tumor xenograft models.(4,16-18) BKM120 (Novartis Pharma AG, Basel, Switzerland) is an oral pyrimidine-derived pan-PI3K inhibitor with specific and potent activ”
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. (2011, background): “The PI3K pathway plays a central role in tumorigenesis across a variety of malignancies (Courtney et al., 2010; Liu et al., 2009).”
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity (2011, positive): “This has led to a major effort to develop inhibitors of PI3K, AKT, mTOR, and other components of the pathway (Courtney et al., 2010; Workman et al., 2010).”
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer (2021, background): “Phosphatase and tensin homolog (PTEN), as a tumor suppressor that dephosphorylates PIP3 into PIP2 for inactivation of AKT and PDK1, negatively regulating the PI3K/AKT/mTOR signaling pathway.(117,123) The PI3K/AKT/mTOR signaling pathway is crucial to many aspects of cell differentiation, growth, apop”